Panel Discussion | LVADS

Sunday, March 8, 2026

9:08 AM - 9:31 AM EST

Location: Georgetown

Moderator(s)

Mandeep R. Mehra, MD, MSc, FRCP

William Harvey Chair in Cardiovascular Medicine
Brigham and Women's Hospital
Needham, Minnesota, United States

Disclosure(s): No financial relationships to disclose
Ryan J. Tedford, MD

Chief, Heart Failure; Peter C. Gazes Chair in Heart Failure
Medical University of South Carolina, South Carolina, United States

Disclosure(s): 35Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing); Abiomed: travel reimbursement (Terminated, February 9, 2026); Acorai: Consulting Fees (e.g., advisory boards) (Ongoing); Adona: Consulting Fees (e.g., advisory boards) (Ongoing); Aria CV: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); CVRx: Travel to meeting (Terminated, February 9, 2026); Edwards Lifesciences LLC: Consulting Fees (e.g., advisory boards) (Ongoing); Endotronix: Consulting Fees (e.g., advisory boards) (Ongoing); Fauna Bio: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Gradient: Consulting Fees (e.g., advisory boards) (Ongoing); Imbria: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Morphic: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Pulmonvant: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Restore Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Tempus AI: Consulting Fees (e.g., advisory boards) (Ongoing); United Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)
Melana Yuzefpolskaya, MD

Associate Professor of Medicine
Columbia Presbyterian Medical Center, New York, United States

Disclosure(s): No financial relationships to disclose

Panel Discussant(s)

Itsik Ben-Dor, MD

WHC
MedStar Washington Hospital Center
Washington, District of Columbia, United States

Disclosure(s): No financial relationships to disclose
Jonathan Grinstein, MD

Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation Physician
University of Chicago
MedStar Washington Hospital Center
Bethesda, Maryland, United States

Disclosure(s): CVRx: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
Jonathan R. Gower, MD

Cardiac Surgeon
Medstar Washington Hospital Center
Arlington, Virginia, United States

Disclosure(s): No financial relationships to disclose
Ileana L. Pina, MD, MPH

Professor of Medicine
Thomas Jefferson University
Cleveland hts, Ohio, United States

Disclosure(s): Nuvance: Advisor (Ongoing)
Changfu Wu, PhD

SBRBPAS Expert
Food and Drug Administration
Silver Spring, Maryland, United States

Disclosure(s): No financial relationships to disclose

Disclosure(s):

Mandeep R. Mehra, MD, MSc, FRCP: No financial relationships to disclose

Ryan J. Tedford, MD: 35Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing); Abiomed: travel reimbursement (Terminated, February 9, 2026); Acorai: Consulting Fees (e.g., advisory boards) (Ongoing); Adona: Consulting Fees (e.g., advisory boards) (Ongoing); Aria CV: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); CVRx: Travel to meeting (Terminated, February 9, 2026); Edwards Lifesciences LLC: Consulting Fees (e.g., advisory boards) (Ongoing); Endotronix: Consulting Fees (e.g., advisory boards) (Ongoing); Fauna Bio: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Gradient: Consulting Fees (e.g., advisory boards) (Ongoing); Imbria: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Morphic: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Pulmonvant: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Restore Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Tempus AI: Consulting Fees (e.g., advisory boards) (Ongoing); United Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)

Melana Yuzefpolskaya, MD: No financial relationships to disclose

Itsik Ben-Dor, MD: No financial relationships to disclose

Jonathan Grinstein, MD: CVRx: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Jonathan R. Gower, MD: No financial relationships to disclose

Ileana L. Pina, MD, MPH: Nuvance: Advisor (Ongoing)

Changfu Wu, PhD: No financial relationships to disclose